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A protein exhibiting endoglycosidase activity was
puri®ed from plantar stratum corneum to apparent
homogeneity in two sequential column chromato-
graphic steps. Protein sequencing revealed its iden-
tity with the recently cloned human heparanase 1,
an enzyme, the expression of which is reported to
be related to the metastasic potential of tumor
cells. By using a heparanase 1 speci®c antibody
we were able to demonstrate that, in the plantar
stratum corneum, heparanase 1 exists in two
forms, the active 50 kDa protein and the inactive
63 kDa form, probably a proform of the enzyme.
The antibody also decorated numerous degradation
fragments. Reverse transcription polymerase chain
reaction studies as well as immunohistochemical
analysis using reconstructed and normal human
epidermis demonstrated clearly a keratinocyte
differentiation related expression of heparanase 1.
Interestingly, the antibody also strongly decorated
dendritic cells, which after double labeling could
be identi®ed to be a subpopulation of the epider-
mal Langerhans cells. Based on our ®ndings and
the known history of this enzyme, we advanced
the hypothesis that heparanase 1 has multiple phy-
siologic functions in the epidermis: (i) it plays an
important role in epidermal differentiation, pos-
sibly by modulating the liberation of heparan sul-
fate bound (growth) factors; (ii) in the stratum
corneum, the endoglycosidase activity of hepara-
nase 1 might be indispensable and represent the
®rst step in the desquamation process; and (iii)
in Langerhans cells, its catalytic activity is
required for the trans-tissue migration of these
cells. Key words: heparanase/heparan sulfate/keratino-
cyte/Langerhans cells/stratum corneum. J Invest
Dermatol 117:1266±1273, 2001
G
lycosaminoglycans (GAG) have been visualized by
electron microscopy in the epidermis as rod-like
granules attached to the keratinocyte cell surface.
Heparan sulfate is the most abundant GAG, present
throughout the epidermis (Tammi et al, 1987).
Keratinocytes in culture are also able to synthesize a variety of
GAG that attached to proteins form a large variety of proteoglycans
(Rahemtulla et al, 1987; Piepkorn et al, 1990). Enzymatic
deglycosylation of these proteins revealed that the majority of the
core proteins are substituted with heparan sulfate (Haggerty et al,
1992). The exact function of epidermal GAG and proteoglycans is
still unknown; however, they are suspected to be associated with a
variety of functions, i.e., cell±cell interactions, cell adhesion,
proliferation, differentiation, morphogenesis, remodeling of the
extracellular matrix, hydration, antimicrobial activity (Ruoslahti,
1989; Ruoslahti and Yamaguchi, 1991), and modulation of the
in¯ammatory response (Lider et al, 1990). In keratinocytes, heparan
sulfate proteoglycans (HSPG) are supposed to modulate prolifera-
tion and differentiation by their ability to affect growth factor
signaling and binding (Piepkorn et al, 1995; LaRochelle et al, 1999).
HSPG might also play an important role in the process of
desquamation as sugar moieties have been demonstrated to protect
the corneodesmosomes from proteolysis. Walsh and Chapman
(1991) described how a sequential action of glycosidases and
proteases is required to degrade the corneodesmosomes.
In the hair follicle, the trans-membrane proteoglycan syndecan,
which may possess both heparan and chondroitin sulfate chains, is
suggested to be important for hair follicle morphogenesis
(Couchman, 1993). The involvement of proteoglycans in hair
growth has been deduced from the fact that in some diseases an
increased presence of skin proteoglycans was associated with
increased hair growth (Westgate et al, 1991).
Modulation of the physiologic functions of HSPG is attributed to
the activity of endoglycosidases named heparanases. Heparanases
are endo-b-D-glucuronidases that degrade GAG chains of HSPG at
speci®c sites. Heparanase activities have been described in various
human cell types and tissues, i.e., platelets, placenta, skin ®broblasts,
smooth muscle cells, umbilical vein endothelial cells, macrophages,
monocytes, and neutrophils (Freeman et al, 1999). Many studies
were performed to investigate the role of human heparanase in
association with the metastasic potential of tumor cells. Vlodavsky
et al (1995) demonstrated that speci®c inhibitors of heparanase
activity were able to block the invasive properties of heparanase
expressing tumor cells and in consequence prevent metastasis.
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Six research teams succeeded almost simultaneously to identify
and clone the human heparanase (Hpa1) (Fairbanks et al, 1999;
Hulett et al, 1999; Kussie et al, 1999; Toyoshima and Nakajima,
1999; Vlodavsky et al, 1999; Dempsey et al, 2000). Very recently
Mckenzie et al (2000) reported the cloning of another human
heparanase family composed of three splicing variants named
Hpa2a, Hpa2b, and Hpa2c, with Hpa2a exhibiting a 35%
homology with Hpa1.
Despite the presence HSPG in human skin, until now no
epidermal heparanase has been identi®ed. By using a modi®cation
of the previously described methods of Toyoshima et al (1999), we
succeeded in identifying and purifying Hpa1 from human plantar
stratum corneum. Here we describe its characterization and
distribution in normal human epidermis and speculate on its
possible role in epidermal physiology.
MATERIALS AND METHODS
Materials Vivaspin ultra®ltration ®lters were from Sartorius
(GoÈttingen, Germany). Premade SDS-PAGE gelbond PAG ®lm-
supported gels for horizontal electrophoresis, Rainbow molecular weight
markers, the silver staining kit, ®rst-strand cDNA synthesis kit, HiTrap
heparin sepharose columns, and gel ®ltration G75 HR16/60 columns
were from Amersham Pharmacia Biotech (Uppsala, Sweden). Taq
polymerase was from Sigma (St. Louis, MO, USA). The RNA
preparation kit RNeasy was obtained from Qiagen (Hilden, Germany).
Oligonucleotides were synthetized by Genset (Evry, France). Premade
INSTA-blot human cell lines and human tissues were obtained from
Calbiochem (San Diego, USA).
Heparanase assay We used a modi®cation of the method previously
described by Toyoshima et al (1999). Heparan sulfate, labeled with
¯uorescein isothiocyanate (FITC-HS), was used as a substrate and
essentially prepared as described before; however, the gel ®ltration
puri®cation step was replaced by a washing procedure to remove
unbound FITC and repetitive concentrations±dilutions on a 30 kDa cut-
off Vivaspin ultra®lter (Sartorius) to eliminate low molecular weight
FITC-HS (<30 kDa). After incubation at 37°C the samples were
immediately separated, avoiding the use of heparin and the boiling of
samples. The detection step by high performance liquid chromatography
(HPLC) was replaced by a horizontal sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) performed on
prefabricated gelbond PAG ®lm-supported gels (12.5% acrylamide
homogeneous gels, or 8±18% gradients) according to the manufacturer's
instructions. Detection of FITC-HS and of its degradation products was
performed on a Fluorimager laser scanner from Amersham Pharmacia
Biotech.
Extracts from plantar stratum corneum and from reconstructed
epidermis Reconstructed epidermis obtained after 13 d of culture
and plantar stratum corneum from volunteers were homogenized in
Tris-buffered saline (TBS), pH 7.2, containing 0.5% (wt/vol) Triton
X100 and a protease inhibitor cocktail (complete EDTA-free from
Roche Molecular used according to the manufacturer's instructions,
complemented with 1 mM pepstatin) on an ice bed (500 ml buffer per
10 mg tissue weight) with a polytron for 1 min before centrifugation
(10,000 3 g for 10 min). Protein content of the supernatant was
quanti®ed using the Bio-Rad protein assay. Samples were adjusted to a
protein concentration of 0.1 mg per ml before performing the
heparanase assay.
Puri®cation of heparanase Plantar stratum corneum of healthy
donors (100 g) was homogenized with a polytron in 600 ml of TBS,
pH 7.2, containing 0.5% (wt/vol) Triton X100 and protease inhibitor
cocktail (complete EDTA-free from Roche Molecular used according to
the manufacturer's instructions, complemented with 1 mM pepstatin) on
an ice bed. The suspension was ®rst ®ltered on a 40 mm mesh Nylon
®lter (Millipore). The resulting supernatants were successively passed
over 1 mm and 0.2 mm Polycap ®lters before chromatographic
separation.
All puri®cation steps were performed at 4°C on a Biologic chromato-
graphy station (Bio-Rad). The extract (600 ml) obtained as described
above was directly loaded on a Hitrap 5 ml heparin sepharose column
previously equilibrated with sample buffer at a ¯ow rate of 2.5 ml per
min. The column was washed with ®ve column volumes of sample
buffer, where Triton X100 had been substituted by its low ultraviolet
absorbing reduced form (buffer A). Elution was performed using the
same buffer containing 1 M NaCl (buffer B) with a gradient from 0% to
100% of buffer B in 20 column volumes; fraction size was 1.05 ml.
Protein elution was monitored by recording the OD280nm. The eluted
proteins were submitted to SDS-PAGE on prefabricated gelbond PAG
®lm-supported gels (8±18% gradient gels) using a 1:2 dilution with 2 3
Laemmli sample buffer and silver stained according to the manufacturer's
instructions. The molecular weight standard used was a mix (1:1) of low
and high molecular weight prestained Rainbow markers (Amersham
Pharmacia Biotech) diluted 1:200 with 1 3 Laemmli buffer. Fractions
were assayed for heparanase activity using 10 ml of the fraction for
100 ml of the assay buffer (50 mM sodium acetate, pH 4.2) containing
2±4 mg of FITC-HS.
The heparin sepharose eluted fractions containing heparanase activity
were pooled (fractions 64±73 included from heparin sepharose chromato-
graphy), and concentrated on a 10 kDa cut-off Vivaspin ultra®lter to a
®nal volume of 2 ml. This sample was directly submitted to gel ®ltration
separation on a G75 H16/60 column, previously equilibrated with the
running buffer (50 mM sodium phosphate, pH 7, with 150 mM NaCl).
Chromatography was performed at a ¯ow rate of 1 ml per min with a
fraction size of 0.5 ml. Fractions were analyzed by SDS-PAGE or used
to determine heparanase activity.
Protein sequencing After acetone precipitation of the puri®ed
proteins (MeÂhul et al, 2000) the precipitated proteins were re-solubilized
in 50 ml 1 3 Laemmli buffer before electrophoresis. Horizontal SDS
electrophoresis was performed on prefabricated gelbond PAG ®lm-
supported gels (12.5% homogeneous gels) according to the
manufacturer's instructions. The molecular weight standard used was a
mix (1:1) of low and high molecular weight prestained Rainbow markers
(Amersham Pharmacia Biotech) diluted 1:4 with 1 3 Laemmli buffer.
The staining was performed with the premade Coomassie stain solution
from Bio-Rad. The apparent molecular weights were calculated using
Quantity One software from Bio-Rad. After staining, the gel was rinsed
twice for 5 min in a MilliQ puri®ed water bath and the protein bands
were recovered with a scalpel. In-gel digestion by trypsin was performed
as described by Kawasaki et al (1990). Peptides were separated by a
tandem HPLC procedure (Kawasaki and Suzuki, 1990) combining an
anion exchange HPLC on a DEAE Hemabio 1000 column
(35 3 1.0 mm ID) from Interchrom (France) followed by a reverse
phase HPLC on a C18 Uptisphere 3 mm ODSB column
(150 3 1.0 mm ID) from Interchrom (France). Peptide sequencing was
performed on an Applied Biosystem 494 device. Matrix-assisted laser
desorption ionization time of ¯ight (MALDI-TOF) mass spectrometry
was performed on Applied Biosystems Voyager DEsuperSTR mass
spectrometer.
Polyclonal antibody The antiheparanase polyclonal antibody was
produced by the CovalAb Society (Lyon, France) by immunizing rabbits
with selected peptide from the Hpa1 sequence. One peptide was
retained as potentially immunizing: DB16CA (KLYGPDVGQPRRKTA,
amino acid residues 264±278 from Swissprot sequence Q9UL39). The
rabbits were immunized with a proprietary protocol (CovalAb) and the
antibody was ®nally af®nity puri®ed. Antibody concentration obtained
after the immuno-puri®cation step was 83 mg per ml.
Reconstructed human epidermis Reconstruction of human
epidermis with normal human keratinocytes was performed as described
previously (Tinois et al, 1991). The reconstructed epidermis was
examined at different times during its reconstruction, starting 1 d after
seeding the cells to day 15 of its culture. To evaluate the effect of
retinoic acid the medium was supplemented with 1 mM retinoic acid
between days 4 and 11 with a medium change each second day. Reverse
transcription polymerase chain reaction (RT-PCR) and Western blot
analysis were performed at the end of the treatment. Untreated cultures
served as control.
Western blot analysis Epidermis from plastic surgery and plantar
stratum corneum were homogenized in 1 3 Laemmli buffer containing
2% (wt/vol) SDS and 200 mM dithiothreitol (500 ml buffer per 10 mg
tissue weight) with a polytron for 1 min and boiled 10 min before
centrifugation (10,000 3 g for 10 min). Proteins in the supernatant were
quanti®ed using the Bio-Rad protein assay to adjust samples to 0.5 mg
protein per ml. Samples from puri®cation steps were diluted 1:1 with 2
3 Laemmli buffer and boiled for 10 min before use. Fifteen microliter
samples were run on 12.5% SDS-PAGE gels. Proteins were transferred
to a PVDF membrane (Immobilon P, Millipore) in the presence of
20 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1% SDS, and 20% (vol/
vol) methanol using a trans-blot cell (Bio-Rad) with a constant voltage of
60 V for 4 h. The ready to use blot containing extracts from different
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human tissues (Insta-blot, Calbiochem) was prewetted with methanol
and rinsed twice with water before applying the detection procedure.
The ®lters were blocked with 25 mM Tris-HCl, pH 7.2, 150 mM
NaCl, and 0.05% (vol/vol) Tween 20 containing 0.5% nonfat milk
(TBSTL), at room temperature for 1 h. Thereafter, ®lters were incubated
overnight at 4°C with the primary monoclonal antibody DB16CA
diluted 1:500 in TBSTL. The ®lters were then washed twice for 5 min
in TBSTL and incubated at room temperature for 2 h with the second
antibody coupled to peroxidase (Sigma), diluted in TBSTL as indicated
by the supplier. The ®lters were washed twice for 5 min in TBS before
the detection procedure. The bands were visualized using the ECL+
substrate system (Amersham Pharmacia Biotech) on a FluorSmax imager
(Bio-Rad). Pre-stained Rainbow molecular weight markers served as
standards and molecular weights were calculated by using the Quantity-
One software (Bio-Rad). For the Insta-blot, the Amido black colored
molecular weight markers on the ®lter were used as reference.
RT-PCR analysis Total RNA was obtained from reconstructed
human epidermis during its differentiation between days 1 and 15. RNA
was prepared using an RNeasy kit. Brie¯y, two samples of the
reconstructed epidermis (1 cm2 each) were homogenized in 300 ml of
lysis buffer (included in the kit) and the cell debris was removed using a
QIA shredder column. cDNA was produced from puri®ed total RNA
using the First-Strand cDNA Synthesis Kit. Expression analysis of Hpa1,
human calmodulin, loricrin, transglutaminase 1 (TGM1),
transglutaminase 3 (TGM3), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was performed by RT-PCR using equivalent
amounts of total RNA (0.1 mg per assay), Taq polymerase, and different
primers (for Hpa1, 5¢-caagaaggaatcaacctttgaag-3¢ and 5¢-
gtagtccaggagcaactgagc-3¢; for calmodulin, 5¢-ataaagatggcgatggcaccat-3¢
and 5¢-ccattgccatccttgtcaaaga-3¢; for loricrin, 5¢-accacggaggcgaaggagtt-3¢
and 5¢-ctggggttgggaggtagttg-3¢; for TGM1, 5¢-gcggcaggagtatgttctta-3¢ and
5¢-agggatgtgtctgtgtcgtg-3¢; for TGM3, 5¢-ctgcgtgctgatggtggag-3¢ and 5¢-
tcattcggctacgtcgatg-3¢; for GAPDH, 5¢-aatcccatcaccatcttcca-3¢ and 5¢-
gtcatcatatttggcaggtt-3¢) under the following conditions: one cycle for
2 min at 95°C, 25±30 cycles at 94°C for 30 s, 55°C±60°C for 30 s,
72°C for 30 s, and one cycle at 72°C for 2 min in parallel. The resulting
PCR products were visualized by Gelstar staining after separation on
2%±3% (wt/vol) agarose gels.
Histochemistry Thin cryosections (5 mm) of skin from plastic
surgery were obtained with a Microm HM500M microtome. Sections
were ®xed in acetone at ±20°C for 5 min and air dried.
Immunohistochemical detection of Hpa1 was performed with
streptABComplex/HRP kit from Dako and AEC detection kit from
Sigma according to the manufacturer's instructions except that the
incubation steps were prolonged to 1 h using DB16CA diluted 1:2 in
phosphate-buffered saline/Tween 20 0.05% (PBST) as primary antibody
and an antirabbit biotinylated secondary antibody from Roche Molecular
diluted 1:200 in PBST. Nuclei were counterstained with hematoxylin.
Immunohistochemical detection of heparan sulfate was performed by
direct labeling with an antiheparan sulfate ¯uorescein conjugate antibody
from Calbiochem (cat. no. 375081) diluted 1:2 in PBS.
The double staining immuno¯uorescence detection of CD1a positive
Langerhans cells and Hpa1 positive cells was performed as follows.
Sections were washed in PBS for 5 min before and after acetone ®xation;
thereafter nonspeci®c binding sites were blocked for 20 min in PBS
containing 2% bovine serum albumin and then for 20 min in PBS
containing 0.2% bovine serum albumin. Sections were then incubated
for 1 h in a mixture containing a 1:50 dilution of a mouse monoclonal
antibody to human CD1a (Becton Dickinson no. 347430) and a 1:2
dilution of the rabbit immunopuri®ed polyclonal antibody DB16CA
speci®c for Hpa1. After incubation and two washes in PBS containing
0.2% bovine serum albumin, sections were incubated in a mixture
containing a 1:64 dilution of an antimouse FITC conjugate antibody
(Sigma no. F-2012) and a 1:400 dilution of an antirabbit-cy3 conjugate
antibody (Sigma no. C-2306). After two washing steps for 5 min in PBS
containing 0.2% bovine serum albumin the sections were mounted in a
mounting medium from Dako (no. S3023) and examined using a DMR
microscope (Leica).
RESULTS
Heparanase puri®cation Heparanase activity in extracts
obtained from plantar stratum corneum and reconstructed human
Figure 1. Heparanase activity in extracts from plantar stratum
corneum and reconstructed epidermis. The activity was detected
using an FITC-HS based assay (see Materials and Methods). SDS-PAGE of
FITC-HS was run on 12.5% acrylamide gel after a 24 h incubation at
37°C in the presence of native extracts from plantar stratum corneum
and from reconstructed epidermis. Control represents heparan sulfate
without any extract. Experiments were performed in triplicate with the
same extract. Fluorescence was detected on a Fluorimager scanner. The
shift toward lower molecular weight of FITC-HS compared to control
signals the presence of heparanase activity.
Figure 2. Heparin sepharose chromatography of plantar stratum
corneum extract. (A) Heparin sepharose chromatography. Solubilized
proteins (150 mg) were loaded on the column and eluted with an NaCl
gradient 0 to 1 M (s). Protein elution was monitored at 280 nm (3/4).
(B) SDS-PAGE analysis. Fractions (7.5 ml) were separated by SDS-PAGE
electrophoresis (12.5% acrylamide gel) and silver stained. Arrows indicate
the molecular weight markers.
1268 BERNARD ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
epidermis could clearly be detected using the FITC-HS based
heparanase assay (Fig 1). Separation of the plantar stratum corneum
extract by af®nity chromatography on a heparin sepharose column
(Fig 2A) revealed that the majority of the proteins exhibit low
af®nity for heparin sepharose and could be eluted with NaCl
concentrations below 0.5 M. We expected heparanase activity to
be eluted with NaCl concentrations above 0.5 M and to be present
in the fractions containing less proteins, i.e., fractions higher than
number 50 (see Fig 2B: SDS-PAGE separation of the af®nity
column fractions). Indeed, heparanase activity was detected in
fractions 63±73 with a clear peak in fraction 69 (Fig 3). For further
puri®cation, the heparanase-containing fractions were pooled to
perform gel ®ltration on a G75 sepharose column. The resulting
fractions were analyzed for their heparanase activity (Fig 4A).
Those exhibiting activity were further analyzed by SDS-PAGE
(Fig 4B). Following G75 sepharose column separation and using
the calibration curve obtained with standard proteins, we calculated
molecular weights of 45 kDa and 21 kDa for the major heparanase
active fractions (Fig 4A, fractions 47 and 75, respectively). After
the subsequent SDS-PAGE separation of fractions 38±56 (Fig 4B),
two proteins were detected, one with a molecular weight of
50 kDa and one with 8 kDa, probably representing the two
subunits forming the heterodimeric structure of activated Hpa1 as
described by Fairbanks et al (1999). The above-mentioned 21 kDa
protein exhibiting heparanase activity could not be detected by
SDS-PAGE (result not shown).
Heparanase identi®cation Sequence analysis after
concentration of the proteins in the highly active fractions by
acetone precipitation con®rmed the identity of the 50 kDa protein
with Hpa1. Three peptides, separated by HPLC after trypsinolysis
of the concentrated proteins and sequenced following the Edman
protocol, revealed the following sequences: (i) AGGEVIDSVT
(amino acid residues 287±296 from Swissprot sequence Q9UL39
for Hpa1); (ii) KADIFINGSQLGEDFIQLHK (amino acid residues
234±253); and (iii) PLRPGSSLGLPAFSYSFFVIRNAK (amino
acid residues 517±540) (Fig 5). For the 8 kDa band, a MALDI-
TOF mass spectrometry analysis of the peptides generated by
trypsinolysis was performed. Mass ®ngerprinting research in the
databases led to the identi®cation of three peptides belonging to the
small subunit of Hpa1 and representing 23% of the sequence of the
little subunit described by Fairbanks et al (1999) (Fig 5).
Figure 4. Analysis of the fractions obtained
after sepharose G75 gel ®ltration. (A)
Heparanase activity detection after separation of
the pooled fractions on a G75 HR16/60 column.
Heparanase activity was detected using the FITC-
HS based assay. SDS-PAGE of FITC-HS was run
on an 8±18% acrylamide gel after 30 min
incubation at 37°C. Fluorescence was detected on
a Fluorimager scanner. The fraction with
maximum activity is marked with an open arrow. A
second activity peak can also be detected and is
marked with a black arrow. (B) SDS-PAGE
analysis. Fractions with the maximum heparanase
activity were separated on an 8±18% acrylamide
gel. The gel was silver stained. PHS lane
represents the pooled heparanase active fractions
after heparin sepharose af®nity chromatography of
the crude extract (see Fig 3).
Figure 3. Gel-shift heparanase activity assay
of the fractions obtained after af®nity
chromatography. Heparanase activity was
assayed using the FITC-HS based assay for each
fraction (see Materials and Methods). SDS-PAGE of
FITC-HS was performed on an 8±18% acrylamide
gel after 1 h incubation at 37°C with the heparin
sepharose fractions. Fluorescence was detected on
a Fluorimager scanner.
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Characterization of Hpa1 using Western blot analysis
(a) Hpa1 from the plantar stratum corneum extracts and puri®ed
fractions In the plantar stratum corneum extracts, Western blot
analysis with the DB16CA antibody revealed three bands (Fig 6A,
lane 1): a 63 kDa band representing probably the inactive proform
of the enzyme; a 50 kDa band, the active form as previously
described by Fairbanks et al (1999); and a 30 kDa band, representing
probably a degradation product. MALDI-TOF mass spectrometry
analysis of the peptides generated from the 63 kDa band provided a
good probability for its identity with the proform of Hpa1 (11
peptides representing 29% of the protein; see Fig 5). Analysis of
fraction 69, containing the highest heparanase activity after heparin
sepharose chromatography separation (see Fig 3), revealed the
50 kDa enzyme and a new 27 kDa form (Fig 6A, lane 2). Western
blot analysis of the pooled fractions (fractions 63±73) made the
63 kDa proform of heparanase reappear (Fig 6A, lane 4).
As expected, the gel ®ltration chromatography step following
heparin sepharose chromatography contributed to a further puri-
®cation without affecting the immunodetection pattern, indicating
that under native conditions the 63, 50, and 27 kDa proteins can
form complexes (Fig 6A, lane 4 compared with lane 3).
(b) Hpa1 from human tissue extracts The Western blot analysis of
an extract prepared from normal human epidermis showed the
presence of multiple bands including the 50 kDa form of Hpa1
(Fig 6A, lane 5). The identity and exact nature of the low
molecular bands (40 and 42 kDa) as well as that of the high
molecular weight 110 and 130 kDa are under investigation. It was
interesting to observe that some high molecular weight bands
detected in the Western blot of human epidermis are also present in
Figure 5. Alignment of sequence data obtained by Edman
sequencing and MALDI-TOF mass spectrometry from the
puri®ed heparanase with the published amino acid sequence of
Hpa1 (Swissprot sequence Q9UL39). Italic letters indicate the signal
peptide position. Bold letters indicate the protein part that is eliminated
as the activation occurs leading to the heterodimeric active form of the
enzyme, i.e., the association between the 8 kDa fragment (double
underlined) and the 50 kDa fragment (single underlined) (Fairbanks et al,
1999). «E» indicates the amino acid sequences obtained by Edman
sequencing of the peptides generated by trypsin from the 50 kDa
puri®ed protein. Peptides generated by trypsin from puri®ed proteins and
with masses obtained by MALDI-TOF mass spectrometry that are
exactly matching the theoretical masses calculated from the published
sequence are indicated as follows: «p» peptides from the 63 kDa band,
«L» peptides from the 50 kDa band, and «S» peptides from the 8 kDa
band. The peptide used for the DB16CA polyclonal antibody
development is boxed.
Figure 6. Western blot analysis using the polyclonal
antiheparanase antibody DB16CA. (A) Lane 1, plantar stratum
corneum; lane 2, fraction number 69 after heparin sepharose
chromatography (see Fig 3); lane 3, pooled fractions (63±73) after
heparin sepharose chromatography; lane 4, fraction number 47 after gel
®ltration chromatography; lane 5, total extract from human epidermis.
(B) Human tissues INSTA-blot: lane 1, brain; lane 2, heart; lane 3, small
intestine; lane 4, kidney; lane 5, liver; lane 6, lung; lane 7, skeletal muscle;
lane 8, testis; lane 9, spleen; lane 10, pancreas. Calculated molecular
weights are indicated on the left and on the right.
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other human tissues (Fig 6A, lane 5, compared with Fig 6B, lanes
2, 3, 4, 8, 10); however, none of the INSTA-BlotTM tissues
demonstrated detectable levels of the 50 kDa heparanase, which
seems to be abundantly expressed in plantar stratum corneum, a
tissue composed of corneocytes, the terminal state of keratinocyte
differentiation.
Hpa1 expression is related to keratinocyte differentia-
tion To investigate a possible differentiation-related expression
of Hpa1 in the epidermis, we performed RT-PCR analysis in
keratinocytes at different time intervals during the reconstruction of
a human epidermis. The time course of Hpa1 expression (Fig 7A)
revealed a strong expression at day 1, followed by a remarkable
reduction to almost absence at day 6. Hpa1 expression was very
high again at day 8, matching the expression pattern of loricrin, a
classical marker of keratinocyte differentiation.
Retinoic acid is known to stimulate keratinocyte proliferation
and to downregulate markers of epidermal differentiation (Schmidt
et al, 1989). A comparative RT-PCR analysis of reconstructed
epidermis exposed to 1 mM retinoic acid during days 4 and 11 of its
culture versus an nontreated sample clearly revealed that Hpa1
expression is strongly reduced in the presence of retinoic acid
(Fig 7B). This downregulation of Hpa1 expression was also
con®rmed by Western blot analysis to occur at the protein level
(data not shown).
Immunolocalization of Hpa1 in normal human
epidermis Figure 8(A) reveals Hpa1 expression in the upper
part of the epidermis, ranging from the stratum granulosum into the
®rst layers of the stratum corneum. In the deeper epidermis, the
DB16CA antibody strongly decorated a dendritic cell population,
which, due to their suprabasal localization, were suspected to be
Langerhans cells. This asumption could be con®rmed by double
staining immuno¯uorescence experiments (Fig 9). The exact
nature of this Hpa1 positive Langerhans cell subpopulation is
under investigation. Immunolocalization of heparan sulfate
(Fig 8B) con®rmed the presence of the heparanase substrate at
the basement membrane between dermis and epidermis and in the
dermis but also showed a faint staining in the suprabasal layers of the
epidermis.
DISCUSSION
The endoglycosidase heparanase is an enzyme that cleaves heparan
sulfate, a major component of the extracellular matrix and basement
membranes. Its expression in mammalian cells is generally associ-
ated with the mediation of tumor metastasis and angiogenesis
(Vlodavsky et al, 2000) and its mRNA expression level is used as a
diagnostic parameter to evaluate the metastatic potential of tumor
cells (Ikuta et al, 2001). So far no heparanase activity has been
described in epidermal cells.
At the base of our investigations was a research program designed
to elucidate the sequence of events implicated in the control of
epidermal desquamation, a process mainly controlled by proteases
that degrade the corneodesmosomal proteins and in consequence
liberate the corneocytes. Sugars have also been described to
modulate desquamation, however. Walsh and Chapman (1991)
demonstrated clearly in their model that the proteolytic degradation
of corneodesmosomes is preceded by endoglycosidase activity, a
process that they de®ned as the ®rst step in desquamation.
Numerous exoglycosidases have been reported in epidermis
(Nemanic et al, 1983) but their implication in the desquamation
process has remained questionable.
By sequencing human stratum corneum proteins exhibiting
heparanase activity after a two-column step puri®cation process, we
were able to demonstrate the presence of what might be the missing
link in the desquamation cascade, the endoglycosidase heparanase
(Hpa1). Using speci®c antibodies generated for the study, we could
con®rm the presence of Hpa1 in the stratum corneum of human
skin, an acidic environment (Ohman and Vahlquist, 1994)
particularly favorable for Hpa1, which exhibits a pH optimum
between 4 and 5. Western blot analysis revealed the presence of
two Hpa1 proteins in the plantar stratum corneum, the 50 kDa
active form of the enzyme and its proform with 63 kDa
accompanied by lower molecular weight forms that we suppose
to be degradation products. A more detailed analysis of puri®ed
Hpa1 (Fig 4B) demonstrated that, as already described by Fairbanks
et al (1999) for human platelet heparanase, epidermal active Hpa1
has a heterodimeric structure and is composed of an 8 and a 50 kDa
chain.
Evidence that Hpa1 expression in human epidermis is not related
to any transformation process but closely related to keratinocyte
differentiation was obtained by RT-PCR studies during the
reconstruction of human epidermis and immunohistochemical
analysis of normal human epidermis. After day 6 of the recon-
struction, Hpa1 expression matched the expression of loricrin, a
classical marker of late keratinocyte differentiation. The relatively
high Hpa1 expression in keratinocytes at day 1 probably indicates a
role of this enzyme in the migration of freshly seeded keratinocytes
to cover the surface of the dermal substrate. One might speculate
Figure 7. RT-PCR analysis of Hpa1 expression. (A) Hpa1
expression in keratinocytes during the reconstruction of human
epidermis. (B) Effect of a 1 mM retinoic acid on Hpa1 expression in
reconstructed human epidermis. The ®gure shows the band intensity of
speci®c amplicon generated by a set of primers corresponding to
differentiation markers (loricrin, TGM1, TGM3) and of two
housekeeping genes (calmodulin, GAPDH) compared with Hpa1 (see
Materials and Methods). The total mRNA (0.1 mg undiluted) was diluted
53 or 203 to evaluate more accurately the respective mRNA levels.
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that Hpa1 might also play an important role in keratinocyte
migration during wound healing.
It was interesting to observe that, besides the stratum corneum,
the Hpa1 speci®c antibody decorated a subpopulation of epidermal
Langerhans cells. After exposure to haptens, these dendritic cells
migrate to the peripheral lymph nodes to present the captured and
processed antigen to T cells. To migrate through the different
tissues and in particular to penetrate the basement membrane,
Langerhans cells are known to express collagenase IV (matrix
metalloproteinase 9) (Kobayashi, 1997; Kobayashi et al, 1999),
another enzyme associated with tumor cell migration (Liotta et al,
1983). Expression of Hpa1 by activated Langerhans cells could be
essential to penetrate the heparan sulfate rich basement membrane
between dermis and epidermis. We are investigating in our in vitro
model (ReÂgnier et al, 1997) the hapten-induced expression of Hpa1
in human epidermal Langerhans cells.
Based on our observations we suppose that Hpa1 plays an
important role in epidermal physiology; however, the determin-
ation of its exact role requires further investigation. Experiments are
in progress to elucidate its role in the desquamation process,
including electron microscopy studies to determine its exact
location within the stratum corneum. As it is known that heparan
sulfate undergoes age-related changes (Feyzi et al, 1998), a study of
the Hpa1 expression in young and aged skin is envisaged, as well as
a monitoring of heparanase expression in the hair follicle, where the
enzyme could be involved in the remodeling of the extracellular
matrix, an important event in the hair cycle.
Figure 9. Double±staining immuno¯uorescence microscopy of
epidermis using antiheparanase and anti-CD1a antibodies.
Distribution of Hpa1 (A, red immuno¯uorescence) in the upper part of
the epidermis and in dendritic cells was con®rmed. A great number of
CD1a positive Langerhans cells (B, green immuno¯uorescence) were
detected in the suprabasal layers of the epidermis. The yellow mix color
(C) in the dendritic cells evidenced that a part of the Hpa1 detected in
the epidermis is produced by a subpopulation of Langerhans cells.
Figure 8. Comparison of the immunolocalization of heparanase
and heparan sulfate in epidermis. (A) Immunohistochemistry using
rabbit polyclonal antibody DB16CA against heparanase as the primary
antibody. Arrows indicate intensively decorated cells in the suprabasal
layers of the epidermis, probably Langerhans cells. (B) Immuno-
¯uorescence using FITC-labeled mouse monoclonal antibody against
heparan sulfate. The dotted line indicates the stratum corneum limits. E,
epidermis; D, dermis. Scale bar: 100 mm.
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